| 项目 | 2024 年度 | | --- | --- | | 营业收入(万元) | 59.746.96 | | 净利润(万元) | 7.350.11 | | 归属于申请挂牌公司股东的净利润(万元) | 7,350.11 | | 扣除非经常性损益后的净利润(万元) | 6.375.03 | | 归属于申请挂牌公司股东的扣除非经常性损益 后的净利润(万元) | 6.375.03 | | 毛利率 | 68.34% | | 加权净资产收益率 | 22.39% | | 加权平均净资产收益率(扣除非经常性损益) | 19.42% | 公开转让说明书显示，绽妍生物有限系张颖霆、税科英、王昆、乔博四位自然人股东共同投资设立。 截至公开转让说明书签署日，张颖霆直接持有公司62.16%股份，通过一致行动人杨丰乐、横琴绽妍间接控制公司1791.2万股股份的表决权，合计控制公司 91.22%股份的表决权，且担任公司董事长、经理，为公司控股股东及实际控制人。 | 辅导对象 | 绽妍生物科技股份有限公司 | | --- | --- | | 成立日期 | 2019年12月6日 | | 注册资本 | 6.162 月元 法定代表人 张颖霍 ...

| 辅导对象 | 绽妍生物科技股份有限公司 | | --- | --- | | 成立日期 | 2019年12月6日 | | 注册资本 | 6.162 月元 法定代表人 张颖霆 | | 注册地址 | 中国(四川)自由贸易试验区成都高新区天府大道中段 666号 2 栋 37 楼 3701 号 | | 控股股东 及持股比 | 公司控股股东为张颖霆,直接持有公司 62.1551%股权 | | 例 | | | 行业分类 | 在其他交易 公司已在全国中小企 场所(申请) C27 医药制造业 业股份转让系统挂 挂牌或上市 牌,股票代码 874888 | | | 的情况 | | 备 注 | 无 | 瑞财经 刘治颖 1月13日，绽妍生物科技股份有限公司（以下简称：绽妍生物）在四川证监局完成IPO辅导备案，拟北交所上市，辅导机构为中国国际金融股 份有限公司。 绽妍生物成立于2019年12月，注册资本6162万元，专业从事生物医用材料、皮肤学级护肤品和生物活性原料的研发、生产和销售。公司于2025年9月挂牌新 三板。 张颖霆，1972年1月出生，本科学历。1995年2月至1998年8月为中国石油乌鲁木齐石油化工有限公司工人；199 ...

Group 1 - The core viewpoint of the article is that Zhan Yan Biotechnology Co., Ltd. has initiated the listing guidance process with the support of China International Capital Corporation [1] - Zhan Yan Biotechnology was established on December 6, 2019, with a registered capital of 61.62 million yuan [1] - The legal representative of the company is Zhang Yingting, who is also the controlling shareholder, holding 62.1551% of the company's equity [1] Group 2 - The company specializes in the research, production, and sales of biomedical materials, dermatological skincare products, and biological raw materials [1] - Zhan Yan has developed several brands, including the dermatological repair brand Zhan Yan, the infant skincare brand Zhan Xiao Yan, and the brand Defilin [1]

Investment Rating - The report maintains an "Overweight" rating for the industry, with a focus on new consumption sectors such as beauty care, IP derivatives, and gold jewelry [5][29]. Core Insights - The report highlights significant market performance for the week of June 23-27, 2025, with retail, social services, and beauty care sectors increasing by 4.56%, 4.61%, and 1.04% respectively, outperforming the Shanghai Composite Index which rose by 1.91% [14][17]. - Key events include the strategic investment of 3.4 billion yuan by Jianbo Biological into Yangshengtang, and the successful IPO of Yingtong Holdings on the Hong Kong Stock Exchange [3][28]. Summary by Sections Market Performance - The retail, social services, and beauty care sectors ranked 9th, 8th, and 24th among 31 primary industries, with notable increases in sub-sectors such as education, professional chains, and trade, which rose by 7.47%, 7.42%, and 5.2% respectively [14][17]. Key Industry Data and News - In the beauty care sector, significant developments include the entry of Kefu Mei into Malaysia's Watsons, becoming the first Chinese efficacy skincare brand in the region, and the announcement by the National Medical Products Administration regarding the management of cosmetic raw materials [23][24]. - Jianbo Biological's restructuring of its collagen product to a medical device category and the successful listing of Yingtong Holdings are also noteworthy [3][24]. Investment Recommendations - The report recommends focusing on companies such as Shangmei Co., Ltd., Juzhi Biological, Marubi Biological, Runben Co., Ltd., Proya, Chaohongji, Blukoo, and Furuida as potential investment targets within the highlighted sectors [5][29].

或许你已经发现，走进家里小区楼下的药店，第一眼看到的可能不是药品，而是薇诺娜、可复 美、绽妍等品牌的护肤产品，这一幕正悄然成为中国药店的"新常态"。 近日，福瑞达生物公布了年内覆盖1 0个千万级OTC连锁的大计划。无独有偶，百雀羚也于年 初宣布正式入驻北京同仁堂渠道。随着线上红利逐渐见顶，不少品牌开始瞄准线下OTC专业渠 道掘金。 《FBe a u t y未来迹》经过调研发现，美妆在OTC渠道的生意，比起未开发的蓝海，更像是一支 蓄势待发的弓箭。在已经跑出薇诺娜这个十亿级销售规模美妆品牌的情况下，依旧还有巨大的 想象空间。 OTC渠道可以说是目前在线下分布最广的一类渠道，正如居民楼附近不一定会有化妆品店，但 一定会有药店，而这不是错觉。 根据薇诺娜母公司贝泰妮集团发布的2 0 2 4年上半年财报，OTC分销渠道销售模式实现营业收 入人民币3 5 , 4 7 0 . 1 4万元，约占主营业务收入1 2 . 7 1%，同比增长约2 0 . 0 1%。 按照这一增速， 薇诺娜在OTC的年销售规模大概率已经迈过1 0亿门槛。 据公开资料，薇诺娜从2 0 1 6年开始与连锁药房合作，彼时市场体量只有5 0万左右；8年后 ...